ETCM
ASND icon

Evolutionary Tree Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Evolutionary Tree Capital Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Sell
6,049
-3,021
-33% -$706K 3.04% 13
2026
Q1 		$2.07M Sell
9,070
-3,211
-26% -$720K 3.9% 11
2025
Q4 		$2.62M Sell
12,281
-3,062
-20% -$632K 3.04% 17
2025
Q3 		$3.05M Sell
15,343
-3,111
-17% -$580K 3.33% 12
2025
Q2 		$3.19M Sell
18,454
-2,202
-11% -$359K 3.38% 14
2025
Q1 		$3.22M Sell
20,656
-9,459
-31% -$1.35M 3.74% 12
2024
Q4 		$4.15M Sell
30,115
-2,638
-8% -$347K 4.22% 8
2024
Q3 		$4.89M Buy
32,753
+7,891
+32% +$1.07M 4.9% 6
2024
Q2 		$3.39M Buy
24,862
+11,223
+82% +$1.53M 3.49% 9
2024
Q1 		$2.06M Sell
13,639
-3,087
-18% -$441K 2.08% 25
2023
Q4 		$2.11M Buy
16,726
+69
+0.4% +$6.88K 2.33% 15
2023
Q3 		$1.56M Sell
16,657
-290
-2% -$27.1K 2.01% 20
2023
Q2 		$1.51M Buy
16,947
+6,295
+59% +$548K 1.82% 19
2023
Q1 		$1.14M Sell
10,652
-11,695
-52% -$1.34M 1.58% 22
2022
Q4 		$2.73M Sell
22,347
-6,799
-23% -$789K 2.62% 15
2022
Q3 		$3.01M Buy
29,146
+6,487
+29% +$615K 2.89% 14
2022
Q2 		$2.11M Sell
22,659
-14,842
-40% -$1.4M 2.29% 21
2022
Q1 		$4.4M Sell
37,501
-5,211
-12% -$604K 3.06% 12
2021
Q4 		$5.75M Buy
42,712
+19,470
+84% +$2.9M 2.76% 20
2021
Q3 		$3.71M Buy
23,242
+5,872
+34% +$804K 1.64% 28
2021
Q2 		$2.29M Buy
17,370
+606
+4% +$80.8K 1.05% 33
2021
Q1 		$2.16M Buy
16,764
+4,552
+37% +$692K 1.28% 30
2020
Q4 		$2.04M Buy
+12,212
New +$2.02M 1.55% 27

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Evolutionary Tree Capital Management's ASND Position: Q2 2026 in Review

Evolutionary Tree Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 33% in Q2 2026, selling an estimated $706K and leaving 6,049 shares worth $1.61M. The position accounts for 3.04% of the portfolio, ranked #13.

Evolutionary Tree Capital Management first reported a position in ASND in Q4 2020 and has held it in 23 quarters since. The position peaked at $5.75M in Q4 2021. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Evolutionary Tree Capital Management held 6,049 shares of Ascendis Pharma A/S worth $1.61M as of Q2 2026.
  • Evolutionary Tree Capital Management sold 3,021 Ascendis Pharma A/S shares in Q2 2026, an estimated $706K.
  • Ascendis Pharma A/S made up 3.04% of Evolutionary Tree Capital Management's portfolio in Q2 2026, its #13 holding.
  • Evolutionary Tree Capital Management first reported a position in Ascendis Pharma A/S in Q4 2020 and has held it in 23 quarters since.
  • Evolutionary Tree Capital Management's Ascendis Pharma A/S position peaked at $5.75M in Q4 2021.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Evolutionary Tree Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.